0 -monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme of de novo synthesis of guanine nucleotides. The isoenzyme IMPDH2 predominates in activated lymphocytes, and its inhibition by MPA is part of standard immunosuppressive regimens. Yet, there are significant unexplained differences in efficacy and tolerability among patients. The objective of this study was to analyze whether frequent variants in the IMPDH2 gene lead to changes in IMPDH activity and to differences in responsiveness to MPA therapy. All 14 exons and intron-exon boundary regions of IMPDH2 were sequenced from genomic DNA probes from 100 healthy individuals. Two novel exonic single-nucleotide polymorphisms were identified in 1% and one intronic polymorphism (rs11706052) in 19% of the study population. Lymphocyte IMPDH activity and proliferation under three MPA concentrations (2.5, 10 and 25 mmol l -1 ) were compared in rs11706052 carriers and wild-type individuals. The presence of rs11706052 polymorphism reduced the antiproliferative effect of MPA on lymphocytes by approximately 50% compared with the IMPDH2 wild-type form at therapeutic relevant concentrations of 10 mmol l -1 and 25 mmol l -1 . We conclude that a poorer response to MPA therapy can be explained in some individuals by the presence of the rs11706052 polymorphism.
Mycophenolic acid (MPA) is a selective inhibitor of inosine 5
0 -monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme of de novo synthesis of guanine nucleotides. The isoenzyme IMPDH2 predominates in activated lymphocytes, and its inhibition by MPA is part of standard immunosuppressive regimens. Yet, there are significant unexplained differences in efficacy and tolerability among patients. The objective of this study was to analyze whether frequent variants in the IMPDH2 gene lead to changes in IMPDH activity and to differences in responsiveness to MPA therapy. All 14 exons and intron-exon boundary regions of IMPDH2 were sequenced from genomic DNA probes from 100 healthy individuals. Two novel exonic single-nucleotide polymorphisms were identified in 1% and one intronic polymorphism (rs11706052) in 19% of the study population. Lymphocyte IMPDH activity and proliferation under three MPA concentrations (2.5, 10 and 25 mmol l -1 ) were compared in rs11706052 carriers and wild-type individuals. The presence of rs11706052 polymorphism reduced the antiproliferative effect of MPA on lymphocytes by approximately 50% compared with the IMPDH2 wild-type form at therapeutic relevant concentrations of 10 mmol l -1 and 25 mmol l - 1 . We conclude that a poorer response to MPA therapy can be explained in some individuals by the presence of the rs11706052 polymorphism.
Introduction
Mycophenolic acid (MPA) acts as a potent, selective, noncompetitive and reversible inhibitor of inosine 5 0 -monophosphate dehydrogenase (IMPDH). It is the rate-limiting enzyme in the conversion of inosine 5 0 -monophosphate (IMP) to xanthosine 5 0 -monophosphate (XMP) at the metabolic branch point of de novo synthesis of guanine nucleotides. The two isoenzymes, IMPDH type I and type II, are products of two distinct but closely related genes on chromosomes 7q31.3-q32 and 3p21.2-p24.2, respectively. They exhibit extensive homology at the nucleic acid and amino-acid levels, suggesting a strong evolutionary pressure for the conservation of function.
pathway for the generation of guanine nucleotides, MPA exerts its primary effect on lymphocytes. 2, 3 The lymphocyte-specific effect of MPA is also because of its 4.8-fold more potent inhibition of IMPDH2, which predominates in activated lymphocytes, compared with that of IMPDH1, which is ubiquitous in all cells. 4 Mycophenolate mofetil and mycophenolate sodium are MPA precursors and widely used to prevent acute allograft rejection and chronic allograft dysfunction in solid organ transplantation. Both are increasingly used as immunomodulators in diseases such as atopic dermatitis, pemphigus vulgaris, rheumatoid arthritis, lupus nephritis, vasculitis, various glomerular diseases, myasthenia gravis, thrombocytopenic purpura and human immunodeficiency virus infection. 5, 6 Despite the lack of adequate drug monitoring methods and several studies showing significant differences in therapeutic efficacy and tolerability among patients, and claiming that several patients do not or only poorly benefit from MPA therapy, 7, 8 MPA has gained widespread acceptance as part of standard immunosuppressive regimens. Accumulating evidence from pharmacokinetic and pharmacodynamic studies shows the necessity to consider individualization of MPA treatment. Differences in the MPA area under the plasma concentration time curve in transplant recipients receiving the same standard dose of mycophenolate mofetil were reported to be up to 10-fold, and in baseline IMPDH activity among patients with end-stage renal disease, this difference was over eightfold. 9, 10 The substantial variability of basal IMPDH activity and MPA effectiveness might be explained by variations within IMPDH genes or in gene expression. 5 Thus, this study was conducted to elucidate a possible role of frequent variants in the IMPDH2 gene in different responsiveness to MPA by testing their functional relevance in vitro in a lymphocyte proliferation assay, as well as measuring IMPDH activity in lymphocyte-enriched peripheral blood mononuclear cells.
Materials and methods

Study population
A total of 100 healthy volunteers were included in this study, which was approved by the ethics committee of the Medical University of Vienna and was performed in accordance with the declaration of Helsinki. Blood was collected from each individual in EDTA-coated tubes after obtaining written informed consent. In all, 20 volunteers out of these 100 were willing to participate in the second phase of the study to test the functional relevance of the detected genetic variant rs11706052: 8 subjects carried this single-nucleotide polymorphism (SNP) and 12 were free of any genetic variant in the IMPDH2 gene. The demographics of the study groups are shown in Table 1 .
Genotyping
To identify the variants of the IMPDH2 gene, all 14 exons and intron-exon boundary regions were sequenced from 100 genomic DNA samples of healthy probands. Genomic DNA was extracted from whole blood using a GenXtract Blood DNA Extraction System (ViennaLab, Vienna, Austria). Primer pairs containing M13 tails were designed to amplify all of the 14 exons as well as intron-exon boundary regions of IMPDH2 (Table 2) . PCRs were performed in a T-Gradient Thermocycler (Biometra, Goettingen, Germany) at a final volume of 10 ml containing 5 ml Ampli Taq Gold Master Mix (Applied Biosystems, Weiterstadt, Germany), 1.6 ml 50% Glycerol, 0.2 ml MgSO 4 (100 mM), 0.6 units PfuTurbo DNA polymerase (Stratagene, Heidelberg, Germany), 0.9 ml pure water, 1 ml of each primer (5.4 pmol ml Sequencing was performed on a CEQ 8000 eight-channel capillary electrophoresis sequencer (Beckman-Coulter). CEQ 8000 software version 9.0 was used to detect mutations. The complete genomic IMPDH2 sequence from the Ensembl Transcript ID ENST00000326739, which is a product of the gene ENSG00000178035, served as reference to determine gene variants in proband IMPDH2 sequences.
Isolation of peripheral blood mononuclear cell suspensions enriched for lymphocytes
Peripheral blood mononuclear cells were isolated from EDTA-anticoagulated venous blood by density gradient centrifugation on Ficoll-Paque Plus (GE Healthcare). The peripheral blood mononuclear cell fraction containing primarily lymphocytes was collected and washed thrice with cold phosphate-buffered saline containing the protease inhibitors aprotinin (1 mg ml -1 ), leupeptin (1 mg ml -1 ) and phenylmethylsulfonyl fluoride (0.5 mmol l -1 ). After resuspending the cells, aliquots of cell suspensions were used for cell counting in an automated counter (Microdiff, Coulter, Krefeld, Germany). According to the manufacturer's instructions, over 99% of platelets, 97% of granulocytes and 95% of erythrocytes were eliminated from blood samples. In repeated blood smears, lymphocytes represented more than 85% of cells (data not shown). Thus, because of enrichment, these cell suspensions will be referred to as lymphocytes rather than as peripheral blood mononuclear cells in this paper.
For determination of enzyme activity, cell suspensions were diluted with distilled water containing the mix of protease inhibitors as described above to yield a final concentration of 1 Â 10 7 cells/100 ml -1 . Cell lysates were immediately frozen at À80 1C until further preparation.
Lymphocyte proliferation assay
In vitro MPA sensitivity assay was performed in 8 individuals carrying the IMPDH2 rs11706052 SNP and in 12 control probands without any SNP in the IMPDH2 gene to evaluate the inhibitory effect of MPA at different concentrations on concanavalin A (Con-A)-stimulated lymphocyte proliferation. For the lymphocyte proliferation assay, cells were resuspended in RPMI 1640 medium (Gibco, Invitrogen, Karlsruhe, Germany) supplemented with 10% human serum and 50 mL ml -1 gentamicin (10 mg ml -1 , Gibco, Invitrogen). In a final volume of 200 ml, 1.5 Â 10 5 lymphocytes/well were plated onto 96-well round-bottom microtiter plates (Falcon, Heidelberg, Germany) in quintuplicate and cultured at 37 1C in a humidified incubator with 5% CO 2 . Cells were preincubated for 30 min with three different concentrations of MPA (2.5, 10 and 25 mmol l -1 ) before the addition of Con-A (2.5 mg ml -1 ) or medium. Cells that had not been pretreated with MPA but were stimulated with Con-A served as controls. After 72 h of culture, lymphocytes were pulsed with 1 mCi/well tritiated thymidine ( 3 H-thymidine, GE Healthcare) and harvested onto filter strips 18 h later. Incorporation of 3 H-thymidine was measured in a 1450 MicroBeta Plus liquid scintillation counter (Perkin Elmer Wallac Inc., Gaithersburg, MD, USA). Counts per minute (c.p.m.) values obtained for Con-A-stimulated samples were corrected for baseline proliferation by subtracting counts Determination of inosine 5 0 -monophosphate dehydrogenase activity Inosine 5 0 -monophosphate dehydrogenase activity was measured in lymphocytes by means of high-performance liquid chromatography by measuring the formation of XMP and guanosine monophosphate from IMP according to a procedure described by Devyatko et al.
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MPA was added to lymphocytes at three different concentrations (2.5, 10 and 25 mmol l -1 ) after the isolation procedure was completed to avoid washing out MPA during the preparation of cell lysates. 12 Intra-and interassay coefficients of variation of the IMPDH assay (reproducibility of the incubation conditions) as determined in a lymphocyte lysate pool of healthy control subjects were 7.7 and 8.2%, respectively. IMPDH activity is expressed as pmol/10 6 cells per hour.
Statistical analysis
The Mann-Whitney U-test was used to analyze differences between study groups. Data were processed with Microsoft Office Excel 2003 (Microsoft Corporation, Redmond, WA, USA) and analyzed with Stata Version 9.0 (Stata Corporation, College Station, TX, USA). Results are expressed as the arithmetic mean ± s.d.
Results
Single-nucleotide polymorphism detection
Three different SNPs were identified in healthy individuals and confirmed by bidirectional sequencing: two are novel exonic variants and one is the known rs11706052 intronic SNP. The identified SNPs and their frequencies are listed in Table 3 .
The new 1333T4A variant (rs72553872) detected in exon 11 is a nonsynonymous heterozygous SNP at residue 414 leading to an amino-acid substitution of methionine to lysine (M414 K).
The novel 1325T4C variant (rs72553873) also detected in exon 11 is a synonymous heterozygous SNP at residue 411 (Y411Y) with no effect at the amino acid level.
At the tenth base pair position of intron 7, the heterozygous nucleotide substitution (IVS7 þ 10T4C) conforms to the known rs11706052 SNP, validated by multiple independent submissions to the reference SNP cluster of NCBI, as well as by frequency or genotype data.
Inosine 5
0 -monophosphate dehydrogenase activity in lymphocytes The total basal enzyme activity of IMPDH as measured in lymphocytes was not different in probands with the rs11706052 intronic SNP compared with that in the wildtype group. With regard to the three concentrations of MPA (2.5, 10 and 25 mmol l -1 ), there was also no significant difference in IMPDH activity between both study groups. Results are listed in Table 4 . 
Discussion
In this study, we provide evidence that the rs11706052 SNP in intron 7 of the inosine monophosphate dehydrogenase 2 gene is associated with a reduced efficacy of MPA to inhibit lymphocyte proliferation. This finding has potential clinical implications for immunosuppression regimens containing MPA.
Although MPA precursors are appreciated for their good tolerability in comparison with other immunosuppressant drugs, they can cause serious adverse effects, such as gastrointestinal intolerance, hematological abnormalities and infections. 13, 14 In spite of the usage of MPA precursors as a part of standard immunosuppressive regimens, some patients do not benefit from MPA therapy. Although some patients are complete nonresponders, others need higher MPA doses to respond adequately. Similarly, some patients show more adverse effects than do others, and hence require dose reductions more frequently. 9, 15 Methods to predict individual MPA drug responsiveness or dose levels necessary for an adequate response are yet to be established. Drug monitoring was never correlated with a lower incidence of therapy failure with mycophenolate mofetil, which was confirmed in a recent study. 16 However, so far, MPA monitoring was performed by measuring plasma concentrations, and pharmacogenetic factors such as polymorphisms were not considered. Thus, there is growing interest in the impact of genetic polymorphisms of drug-metabolizing enzymes and transporters on drug efficacy. The most significant effects in transplant patients are currently believed to be on the drug-metabolizing enzyme CYP3A as well as on the drug transporter P-glycoprotein. 17 Recent research showed that certain gene polymorphisms have a profound effect on patients' response to drug therapy. For instance, the MDR-1 (P-glycoprotein) 3435C4T polymorphism in the multidrug-resistance type I gene was associated with acute persistent rejection in lung transplant recipients. 17 Kidney transplant recipients with the CYP3AP1*1 genotype require up to twofold higher doses of tacrolimus to achieve comparable blood levels at 3 months after transplantation compared with patients with the CYP3AP1*3/*3 genotype. 18 SNPs can be associated with functional differences of proteins or diseases even if they are intronal and are not transcribed. One of the most established examples for such an effect is the significant association of the intronic rs708487 polymorphism in the prostanoid DP receptor gene with asthma. 19 In MPA metabolism, processes such as glucuronidation, carried out by uridine 5 0 -diphospho-glucoronosyltransferases, and active biliary secretion, performed by the multidrug resistance-associated protein-2, are under genetic control, and polymorphisms contribute to the large variability in MPA pharmacokinetics. 5, 14 Furthermore, polymorphisms in the multidrug-resistance type I gene have been associated with gastrointestinal side effects of MPA therapy. 15 As IMPDH2 has an important role in purine metabolism and as MPA exerts its main effect on this enzyme, we searched for polymorphisms in the IMPDH2 gene, which might explain the varying efficacy of MPA therapy among patients. We identified three SNPs. Two novel exonic SNPs, rs72553872 and rs72553873, were present in 1% of the study population and thus did not provide a valid explanation for the nonresponsiveness to MPA, which varies between 20 and 60.5% depending on study design. 13, 20 The third SNP was a known intronic SNP (rs11706052) and occurred in 19% of healthy individuals in our study, corresponding to earlier data from the NCBI SNP database showing the presence of this polymorphism in 20.8% of Caucasians, representing a possible explanation for differences in MPA efficacy. Yet, its functional relevance is still unknown. To study whether it has any effect on MPA efficacy, we performed a high-performance liquid chromatographybased IMPDH activity measurement in lymphocytes and an in vitro lymphocyte proliferation assay at three different concentrations of MPA (2.5, 10 and 25 mmol l -1 ) in carriers and noncarriers of this SNP. As drug treatment may cause alterations in enzyme activity and lymphocyte proliferation, we exclusively recruited healthy probands with no signs of acute or chronic illness and who were taking no drugs. In the lymphocyte proliferation assay, we showed that the presence of the rs11706052 polymorphism reduced the inhibitory effect of MPA on lymphocyte proliferation by approximately 50% compared with IMPDH2 wild-type probands at concentrations of 10 mmol l -1 and 25 mmol l -1 . This suggests that, although immunosuppression through inhibition of lymphocyte proliferation still seems achievable in carriers of SNP rs11706052 by MPA, higher than conventional levels are necessary for an adequate response. We found in wild-type individuals that a therapeutically moderate MPA level of 10 mmol l -1 was effective for producing an approximately 300-fold inhibition of Con-A-stimulated lymphocyte proliferation, whereas in the rs11706052 SNP carriers, 25 mmol l -1 MPA was needed for a similar inhibition. Our findings are affirmed by a recent study showing that renal transplant patients carrying the rs11706052 SNP were three times more likely to experience biopsy-proven acute rejection at 3 months, as well as at 12 months after transplantation, under immunosuppressive therapy containing MPA. 21 On the other hand, our results detect no relationship between the IMPDH2 rs11706052 polymorphism and basal IMPDH activity or enzyme activity during treatment with any of the tested concentrations of MPA. IMPDH activity was tested in native, untreated lymphocytes (without Con-A stimulation) because changes in enzyme activity are likely to occur under cell culture conditions over time. However, measurement of IMPDH enzyme activity by means of highperformance liquid chromatography in lymphocytes has a shortcoming. This method does not differentiate between enzyme activity of IMPDH1 and IMPDH2. IMPDH1 is primarily expressed by resting lymphocytes, whereas IMPDH2 predominates in activated lymphocytes, which represent the more relevant group in organ rejection. Thus, although the total IMPDH activity as measured in lymphocytes remains unchanged, IMPDH2 activity might be different in both groups. As IMPDH2 exhibits a 4.8-fold higher sensitivity to MPA compared with IMPDH1, even slight changes in MPA concentration might lead to relevant consequences in lymphocytic response. Therefore, although our results on IMPDH activity show that the rs11706052 polymorphism does not significantly change total IMPDH activity, they do not allow specific conclusions for IMPDH2. A possible explanation for the unchanged IMPDH activity is that the fraction of activated lymphocytes in healthy volunteers is too small to make a detectable effect in total IMPDH activity, or that any decrease in IMPDH2 is compensated by an increase in IMPDH1 activity.
In conclusion, we showed that MPA has a significantly less antiproliferative effect on lymphocytes in healthy individuals carrying the intronic rs11706052 SNP compared with wild-type individuals. To confirm these findings and to test the clinical relevance of our data in larger study populations and transplant patients, prospective clinical studies are underway at our center. Understanding the role of genetic polymorphisms in MPA responses may help to increase drug efficacy and decrease side effects by tailoring MPA therapy to the genetic makeup of individuals.
